Last reviewed · How we verify
Motilium
At a glance
| Generic name | Motilium |
|---|---|
| Also known as | Domperidone |
| Sponsor | Rabin Medical Center |
| Target | Aldehyde oxidase, Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2 |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
- Nausea and vomiting
Common side effects
Key clinical trials
- Comparison of Shenqu Xiaoshi Oral Liquid and Domperidone Suspension in the Treatment of Functional Dyspepsia in Children: a Randomized, Double-blind, Double-simulated, Multi-center Clinical Study (Phase 4)
- Domperidone Expanded Access Program for Oncology Patients With Gastroparesis Who Have Failed Standard Therapy (N/A)
- Oral Domperidone for Relief of Gastrointestinal Disorders in Patients Who Failed Standard Therapy (NA)
- Cardiac Safety Evaluation of Lansoprazole/Domperidone 30/30 mg Sustained Release Capsule Formulation (Phase 4)
- Volume Sensitive Multichannel Intraluminal Impedance (vMII) for the Measurement of Oesophageal Bolus Transport and Reflux (NA)
- A Randomized, Double-Blind, Placebo- and Positive-Controlled, Single- and Multiple-Dose, 4-Way Crossover Study to Evaluate the Effects of Domperidone on Cardiac Repolarization in Healthy Subjects (Phase 1)
- Use of Domperidone and Risk of Serious Cardiac Events in Postpartum Women (N/A)
- Pragmatic Clinical Trials in Scleroderma (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Motilium CI brief — competitive landscape report
- Motilium updates RSS · CI watch RSS
- Rabin Medical Center portfolio CI